Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.62 |
| ▸ | KDR | P35968 | 10/20 | 0.62 |
| ▸ | SRC | P12931 | 7/20 | 0.62 |
| ▸ | AURKA | O14965 | 6/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.62 |
| ▸ | LCK | P06239 | 2/20 | 0.62 |
| ▸ | RET | P07949 | 2/20 | 0.62 |
| ▸ | MET | P08581 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | LTK | P29376 | 2/20 | 0.62 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.62 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.62 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | FYN | P06241 | 1/20 | 0.62 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.62 |
| ▸ | TTK | P33981 | 1/20 | 0.62 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.62 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.62 |
| ▸ | BTK | Q06187 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13749953 | 0.94 | SRC (0.62) | EGFRKDRSRCAURKAAURKB | |
| SCHEMBL13750138 | 0.90 | SRC (0.66) | EGFRKDRSRCAURKALCK | |
| SCHEMBL6501476 | 0.86 | EGFR (0.60) | EGFRKDRSRCAURKAAURKB | |
| SCHEMBL4414825 | 0.86 | SRC (0.62) | EGFRKDRSRCAURKAAURKB | |
| SCHEMBL3489277 | 0.86 | KDR (0.50) | EGFRKDRAURKB | |
| SCHEMBL14217419 | 0.84 | AURKA (0.74) | EGFRKDRSRCAURKAAURKB | |
| SCHEMBL14216876 | 0.80 | AURKA (0.69) | EGFRKDRSRCAURKAAURKB | |
| SCHEMBL5653890 | 0.80 | AURKA (0.75) | EGFRKDRSRCAURKAAURKB | |
| Gefitinib SCHEMBL17241429 | 0.79 | EGFR (0.90) | EGFRKDRSRCAURKALCK | |
| SCHEMBL14421400 | 0.79 | SRC (0.68) | EGFRKDRSRCAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463506-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| EP-1463506-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-7402585-B2 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-7402585-B2 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | disclosed |
| EP-1463506-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | Astrazeneca AB (SE) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003055491-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | AURKC, AURKA, AURKB | EGFR 1016/4885KDR 933/4885SRC 785/4885 |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | AURKC, AURKA, AURKB | EGFR 920/4885KDR 960/4885SRC 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.